Business Wire

AXELSPACE

17.7.2024 10:01:35 CEST | Business Wire | Press release

Share
Axelspace Announces New Service “AxelLiner Laboratory (AL Lab)” to Meet the Rapidly Growing Need for In-orbit Demonstration of Space Components

Axelspace Corporation announced the launch of AxelLiner Laboratory (AL Lab), a new service under AxelLiner introduced in 2022. This service specializes in in-orbit demonstration of space components with sales set to begin in the near future.
Additionally, a new memorandum was signed between Axelspace and ASPINA Shinano Kenshi Co., Ltd., a partner in developing a reaction wheel for microsatellites since 2020. The companies have agreed to launch the wheel in 2026 and conduct an in-orbit demonstration, making it the first to utilize AL Lab.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240717515842/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

AxelLiner Laboratory is a new service under AxelLiner introduced in 2022. This service specializes in in-orbit demonstration of space components with sales set to begin in the near future. (Graphic: Business Wire)

Axelspace announcement
https://www.axelspace.com/news/axellinerlaboratory/

Meeting the growing need for in-orbit demonstration

Introducing AxelLiner in 2022, Axelspace has been preparing for its full-scale service launch. This preparation included developing a versatile bus system for microsatellites, forming the Spacecraft Manufacturing Alliance for mass production, and building AxelLiner Terminal, a software system offering innovative customer experiences.

Since its business launch, there have been high expectations for this one-stop microsatellite service that enables customers to actualize their unique space missions in a shorter period of time, reaffirming the strong need for this business.
Furthermore, through communications with various space industry players, strong interest has been received from companies that develop space components and mission equipment as well. To further expand this customer base, Axelspace began research into creating a new service for AxelLiner that specializes in in-orbit demonstrations.

The Japanese government plans to create the Space Strategic Fund this year, aiming to offer 1 trillion yen worth of support in the coming decade. One of the themes the fund intends to implement is the establishment of a satellite supply chain through development and demonstration of satellite parts and components. Consequently, the demand for early-phase in-orbit demonstration services is expected to increase in the future.
To overcome these existing challenges involved in in-orbit demonstrations, Axelspace has developed a service tailored to such special needs by leveraging the short development time and mass-production capabilities realized by AxelLiner.

AL Lab can be used not only to test components and mission equipment in space, but also for purposes of entertainment, or corporate or product promotions.
The original service concept will be redefined as “AxelLiner Professional (AL Pro),” with preparations continuing for its full-scale launch.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240717515842/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 07:00:00 CEST | Press release

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3 It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4 Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the

Stonebranch is Again Named a Leader in the 2026 Gartner® Magic Quadrant™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 17:00:00 CEST | Press release

Gartner recognizes Stonebranch as a Leader for the third consecutive year based on Completeness of Vision and Ability to Execute. Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build

Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 16:09:00 CEST | Press release

New facility in Cummings Research Park brings engineering closer to customers while advancing mission processing technologies and strengthening Frontgrade's long-term investment in Huntsville Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboratio

Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release

Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release

Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye